Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

pSivida Inc.

Division of pSivida Ltd./pSivida Inc.
www.psivida.com

Latest From pSivida Inc.

Finance Watch: Anchiano, TCR2, Hoth And Stealth Make Seven US Biopharma IPOs For 2019

Public Company Edition: Four more IPOs in the US bring the year's total to seven – all in February. Also, Agenus launched its digital security offering, MacroGenics leads recent follow-on offerings and four companies reveal new job cuts.

Financing Business Strategies

Early Yutiq Approval Gives EyePoint Two Ophthalmic Drugs To Launch In 2019

Yutiq, for posterior uveitis, will compete with two existing steroid products and should launch during the first quarter of 2019. EyePoint’s Dexycu, although approved in February, is still in scale-up and probably will launch a bit later.

Approvals Ophthalmic

Finance Watch: Is The IPO Boom Making Anyone Nervous Yet?

Public Company Edition: Is the IPO bubble getting ready to burst? It's anybody's guess, but biopharma companies are forging ahead, having launched 11 first-time offerings during the past week and a half. Also, Heron leads recent follow-on offerings with a $200m stock sale to fund what may soon be its third commercial product.

Financing Business Strategies

Devices Expand Their Role in Retinal Disease

Four years following FDA approval, Lucentis remains the standard of care for the treatment of neovascular (wet) age-related macular degeneration (AMD) and has been widely adopted for off-label treatment of other retinal diseases. Companies are pursuing new drugs that may have more favorable dosing profiles, device-based technologies that may reduce the dosing frequency of Lucentis, and implantable drug delivery vehicles designed to deliver drugs to the back of the eye that may be applicable to a broad range of retinal therapies.
Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
    • Implantable Devices
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Site Specific
  • Therapeutic Areas
  • Cancer
  • Musculoskeletal & Connective Tissue Disorders
  • Ophthalmic
  • Alias(es)
  • Control Delivery Systems Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • pSivida Ltd.
  • Senior Management
  • Paul Ashton, PhD, Pres. & CEO
    Michael J Soja, VP, CFO
    Robert Shimizu, VP, Bus. Dev.
    Kenneth Walters, SVP, R&D & Clinical Affairs
  • Contact Info
  • pSivida Inc.
    Phone: (617) 926-5000
    313 Pleasant St.
    Watertown, MA 02472
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register